These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17497760)

  • 41. Identification of rat and human cytochrome p450 isoforms and a rat serum esterase that metabolize the pyrethroid insecticides deltamethrin and esfenvalerate.
    Godin SJ; Crow JA; Scollon EJ; Hughes MF; DeVito MJ; Ross MK
    Drug Metab Dispos; 2007 Sep; 35(9):1664-71. PubMed ID: 17576809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk assessment of Pseudomonas aeruginosa in water.
    Mena KD; Gerba CP
    Rev Environ Contam Toxicol; 2009; 201():71-115. PubMed ID: 19484589
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Using ontogeny information to build predictive models for drug elimination.
    Alcorn J; McNamara PJ
    Drug Discov Today; 2008 Jun; 13(11-12):507-12. PubMed ID: 18549977
    [TBL] [Abstract][Full Text] [Related]  

  • 45. On the incorporation of chemical-specific information in risk assessment.
    Clewell HJ; Andersen ME; Blaauboer BJ
    Toxicol Lett; 2008 Aug; 180(2):100-9. PubMed ID: 18588959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and specification of physiologically based pharmacokinetic models for use in risk assessment.
    Clewell RA; Clewell HJ
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):129-43. PubMed ID: 18077066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inducibility of drug-metabolizing enzymes by xenobiotics in mice with liver-specific knockout of Ctnnb1.
    Braeuning A; Sanna R; Huelsken J; Schwarz M
    Drug Metab Dispos; 2009 May; 37(5):1138-45. PubMed ID: 19237511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.
    Wijnen PA; Op den Buijsch RA; Drent M; Kuijpers PM; Neef C; Bast A; Bekers O; Koek GH
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():211-9. PubMed ID: 18081664
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An adjustment factor for mode-of-action uncertainty with dual-mode carcinogens: the case of naphthalene-induced nasal tumors in rats.
    Bogen KT
    Risk Anal; 2008 Aug; 28(4):1033-51. PubMed ID: 18564993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene.
    Liao KH; Tan YM; Clewell HJ
    Risk Anal; 2007 Oct; 27(5):1223-36. PubMed ID: 18076492
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An underlying role for hepatobiliary dysfunction in cyclosporine A nephrotoxicity.
    Aleo MD; Doshna CM; Fritz CA
    Toxicol Appl Pharmacol; 2008 Jul; 230(1):126-34. PubMed ID: 18407308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Renal function and pharmacotherapy in children].
    Jovanović O
    Srp Arh Celok Lek; 1995 Jun; 123 Suppl 1():15-21. PubMed ID: 18193796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chloroprene: overview of studies under consideration for the development of an IRIS assessment.
    Pagan I
    Chem Biol Interact; 2007 Mar; 166(1-3):341-51. PubMed ID: 17234169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fetal and neonatal hepatic tumors.
    Isaacs H
    J Pediatr Surg; 2007 Nov; 42(11):1797-803. PubMed ID: 18022426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers.
    Meyer MR; Peters FT; Maurer HH
    Drug Metab Dispos; 2008 Nov; 36(11):2345-54. PubMed ID: 18725511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Practical application of kinetic data in risk assessment--an IPCS initiative.
    Meek B; Renwick A; Sonich-Mullin C;
    Toxicol Lett; 2003 Feb; 138(1-2):151-60. PubMed ID: 12559699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.